Clinical experiments have just begun, which may take decades to complete. But may have life changes Researchers are testing drugs that eliminate microbes for Alzheimer's disease in young people who have been genetic in the development of violent brain disorders.
Researchers at the Faculty of Medicine, Washington University are leaders. studyWhich is a test of an antibodies developed by the ELI LILILY company. This drug is given to people younger than 18 years of age, which is highly risky for Alzheimer's first set. Although it may take up to 25 years to know whether these drugs can work according to hope or not. But it takes less time to receive in -depth information about the nature of Alzheimer's.
The drug used in the experiment is called Reminetug. It is intended to be the Donaneemab's Donanamab's successor (KISUNLA brand), which is That has been approved In the treatment of Alzheimer's disease in early July 2024, Donanemab, Remternetug and similar drugs, trying to treat Alzheimer's targeting to the beta -beta protein. In people with Alzheimer's disease, the beta -beta, which was created in the brain, finally became a group known as the shield. (Another wrong protein has an important role.
While Amyloid drugs are the first approval method that is considered to slow down the progress of Alzheimer's current treatment. Effect– It is well known that Amyloid shields can begin to build in the brain 20 or more before someone starts to show the signal of Alzheimer's. And that leads to speculation, these drugs may be more effective and able to prevent Alzheimer's Alzheimer's Alzheimer. This last time has a direct aim.
The study called the preliminary prevention experiment will register 240 people from the family that is known to mutations in one -third genes that often result in the first phase Alzheimer's Alzheimer's patient. It includes people with these mutations, just like relatives who are not service providers to act as a control group. People are eligible to be educated if they are younger than the age of 11 to 25 years, aged they expect to develop Alzheimer's history according to their family history. (Generally, in the 30s aged 40 or 50s)
The main part of the experiment is conducted for two years, with a random participant to receive drugs or pills every three months. After that, people will be able to use the drug openly for another four years if they choose. Due to the volunteers, the researchers did not expect any changes to their perception during the trial. But they will be able to see that the reminder can be clearly slower or even stop the accumulation of Amyloid microbes in the brain of people.
“My grandfather died from Alzheimer and his mother and everyone. But is one of his brothers, “Hannah Richardson, 24 years old. statement Prepared by the Faculty of Medicine, Washington University “I am happy to be involved in preliminary prevention experiments and participate in research because I know how important it is.”
The researchers said that it would take about four to five years to report the research from the first step of the experiment, while all studies were completed by 1974, but they plan to keep an eye on the person. This illness Many years after that. And the lessons that we learn from this research tend to help scientists understand both early and classic Alzheimer's
“The innovative education in the population of this special Alzheimer's patient has significant potential to have significant impact that we prevents Alzheimer's disease, helping people and families from Anguis. Of this serious disease